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Noninhibitory PAI-1 enhances plasmin-mediated
matrix degradation both in vitro and in experimental
nephritis
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Plasminogen activator inhibitor-type 1 (PAI-1) is thought to
be profibrotic by inhibiting plasmin generation, thereby
decreasing turnover of pathological extracellular matrix
(ECM). A mutant, noninhibitory PAI-1 (PAI-1R) was recently
shown by us to increase glomerular plasmin generation and
reduce disease in anti-thy-1 nephritis. Here, in vitro and in
vivo studies were performed to determine whether enhanced
plasmin-dependent ECM degradation underlies the
therapeutic effect of PAI-1R. 3H-labeled ECM was produced
by rat mesangial cells (MCs). The effect of wild-type PAI-1
(wt-PAI-1) and PAI-1R on ECM degradation by newly plated
MCs was measured by the release of 3H into medium. In vivo,
anti-thy-1 nephritis was assessed in normal, untreated
diseased and PAI-1R treated rats with or without the plasmin/
plasminogen inhibitor, tranexamic acid (TA). wt-PAI-1 totally
inhibited plasmin generation and reduced ECM degradation
by 76% when exogenous plasminogen was added. Although
PAI-1R alone had no effect, PAI-1R in the presence of
wt-PAI-1 reversed the wt-PAI-1 inhibition of ECM degradation
in a time- and dose-dependent manner (Po0.001). Plasmin
activity and zymography were consistent with ECM
degradation. Plasmin inhibitors: a2-antiplasmin, aprotinin,
and TA completely blocked PAI-1R’s ability to normalize ECM
degradation (Po0.001). Consistent with the in vitro results,
TA reversed PAI-1R-induced reductions in glomerular fibrin
and ECM accumulation. Other measures of disease severity
were either unaltered or partially reversed. PAI-1R reduces
pathological ECM accumulation, in large part through
effectively competing with native PAI-1 thereby restoring
plasmin generation and increasing plasmin-dependent
degradation of matrix components.
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Progressive accumulation of extracellular matrix (ECM) in
glomeruli and interstitium characterizes chronic renal
disease, regardless of the underlying etiology.1,2 Current data
strongly suggest that decreased ECM degradation contributes
to matrix accumulation,3 and that ECM degradation is
largely controlled by the plasminogen activator (PA)/
plasminogen/plasmin system.3–5 Plasmin, produced by the
action of urokinase type plasminogen activator (uPA) or
tissue type plasminogen activator (tPA) on plasminogen, is
involved in ECM degradation directly by degrading matrix
proteins fibronectin, laminin, proteoglycan, and type IV
collagen as well as fibrin,6–8 and indirectly by converting
inactive matrix metalloproteinases to active forms that
degrade collagenous proteins.9–11 Plasminogen activator
inhibitor-type 1 (PAI-1), as the principal inhibitor of uPA
and tPA, regulates the formation and activity of plasmin.
Increased PAI-1 and decreased PA and plasmin have been
reported in many experimental and human glomerular
diseases characterized by mesangial matrix accumulation.12
The importance of PAI-1 in normal glomerular mesangial
matrix turnover was clearly shown when matrix degradation
increased four-fold after a monoclonal antibody to PAI-1 was
added to cultured mesangial cells (MCs).13 That PAI-1
facilitates ECM accumulation in vivo was shown in the
bleomycin model of pulmonary fibrosis when decreased
fibrosis was seen in PAI-1-deficient and increased fibrosis was
seen in PAI-1-overexpressing mice.14
Based on the physicochemical properties of PAI-1, the
mutant PAI-1R was constructed on the background of a
stable wild-type (wt) PAI-1 mutant with half-life of 142 h.15
PAI-1 proteinase inhibition was disabled by the introduction
of two Arg residues at positions 333 and 335 (residues P14
and P12 of the reactive center loop).16 These residues are near
the hinge region of the reactive center loop and, upon
reaction with a proteinase, normally fold into b-sheet A with
their side chains oriented towards the interior of PAI-1.
Mutations in this region greatly reduce the rate of
conformational rearrangement associated with proteinase
inhibition, abolishing the molecules inhibitor capacity.17
These two substitutions would be expected to greatly retard
the insertion of the reactive center loop into b-sheet A upon
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interaction with a proteinase and also prevent the mutant
from adopting the latent conformation. Since loop insertion
also results in loss of vitronectin (Vn) affinity, PAI-1R not
only fails to inhibit all proteinases but retains significant Vn
affinity.16 Investigating the therapeutic potential of this
mutant, we have recently shown that PAI-1R administration
to nephritic rats increases glomerular plasmin generation and
reduces disease.18 The studies reported here were designed to
test the hypothesis that the therapeutic effect of PAI-1R
involves enhanced plasmin-dependent ECM degradation.
Tranexamic acid (TA) inhibits plasmin proteolysis by
blocking lysine binding sites on plasminogen and plasmin.
TA blocks plasmin(ogen) binding to its proteolytic sub-
strates19,20 and interferes with plasminogen binding to
cellular receptors, where cell surface-bound uPA efficiently
converts it to plasmin.21 TA has been successfully used in
mice with bleomycin-induced pulmonary fibrosis to show
that the disease reduction observed in PAI-1 null mice is
plasmin-dependent.22 We use TA here to determine whether
the therapeutic effect of PAI-1R is plasmin-dependent.
RESULTS
Study 1
Composition of ECM produced by MCs. Immunofluorescent
staining revealed that ECM produced by MCs in vitro was
similar to that in vivo and contained type IV collagen,
fibronectin, and laminin. Vn was also included in the ECM
(Figure 1). Although this Vn could have been produced by
MCs, it is likely that it was deposited from the serum present
in culture medium during MC matrix production. Without
primary antibodies, no staining was seen.
Dependence of ECM degradation on added plasminogen. In
the absence of exogenously added plasminogen, no 3H was
released into culture medium. In contrast, addition of
4mg/ml plasminogen (Chromogenix-Instrumentation Labo-
ratory SpA, V le Monza, Milano, Italy) resulted in 82% of
total counts being released in 72 h (data not shown).
Although plasminogen, the substrate for plasmin generation,
is in high concentration in plasma and therefore normally
available to MCs in vivo, this result indicates that plasmino-
gen is not present in this culture setting and must be added in
order to observe matrix degradation.
Effects of wt-PAI-1 and PAI-1R on degradation of matrix
proteins in vitro. As shown in Figure 2a, addition of wt-PAI-
1 in the presence of exogenous plasminogen for 72 h reduced
the release of 3H into medium in a dose-dependent manner
(*Po0.01 vs Control). When 1.5 107 M wt-PAI-1 was
added for 24, 48, or 72 h, release of 3H into medium was
reduced by 76% (Po0.001) (Figure 2b). In striking contrast,
addition of PAI-1R at 1.5 107 M had no effect on the
Col IV FN
VNLM
Figure 1 | Immunofluorescent staining for ECM produced in vitro
by MCs. Original magnification  400. Col IV, Collagen type IV; FN,
fibronectin; LM, lamin; VN, vitronectin.
0
20
40
60
80
100
120
EC
M
 d
eg
ra
da
tio
n
%
 o
f c
on
tro
l
0
24 h 48 h 72 h 24 h 48 h 72 h
20
40
60
80
100
120
EC
M
 d
eg
ra
da
tio
n
%
 o
f c
on
tro
l
Control
Control
1.8×10−8 3.7×10−8
wt-PAI-1 (M)
wt-PAI-1
7.5×10−8 15×10−8
*
*
*
*
a
b
Figure 2 | Dose (a) and time (b) effects of wt-PAI-1 on ECM
degradation. *Po0.01 vs control.
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Figure 3 | Effect of PAI-1R alone on ECM degradation (a) and
the protective effect of PAI-1R on wt-PAI-1-induced inhibition of
ECM degradation (b–d). (c) *Po0.05 vs wt-PAI-1 alone treated.
(d) *Po0.05 vs control, #Po0.05 vs wt-PAI-1 alone treated for 72 h.
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release of 3H (Figure 3a). When both PAI-1R and wt-PAI-1
were added together at 1.5 107 M for 72 h, the inhibition of
release of 3H seen with wt-PAI-1 was significantly reversed by
PAI-1R (Figure 3b, Po0.001). This effect is dependent on the
dose of PAI-1R added (Figure 3c) and becomes significant
when PAI-1R is added at half the dose of wt-PAI-1. As shown
in Figure 3d, the ability of PAI-1R to reverse wt-PAI-1-
induced inhibition of release of 3H is decreased if PAI-1R was
added later than wt-PAI-1. A partial but significant (Po0.05)
reversal was seen if PAI-1R was added for the last 24 or 48 h.
Overall, the results indicate that wt-PAI-1 almost completely
blocks mesangial matrix degradation while PAI-1R does not.
Importantly, mutant PAI-1R can reverse the wt-PAI-1-
induced inhibition of degradation.
Corresponding results of plasmin activity and plasmin
zymography are shown in Figure 4. 1.5 107 or 3 107 M
PAI-1R had no effect on plasmin activity in culture
supernatant or in the ability of supernatant to degrade
casein (Figure 4a and b, third and fourth bars and lanes). In
contrast, wt-PAI-1, added at the same concentrations, totally
blocks the plasmin activity and degradation of casein seen in
the cell-only control (Figure 4a and b, fifth and sixth bars and
lanes). The last two lanes of Figure 4a and b indicate that
when PAI-1R and wt-PAI-1 are both added at 1.5 107 or
3 107 M, plasmin activity and casein degradation are
partially reversed toward the cell control value. The ability
of PAI-1R to normalize ECM degradation was completely
blocked by each of three plasmin inhibitors (a2-antiplasmin
(40 mg/ml), aprotinin (68 mg/ml) and TA (50 mg/ml),
Po0.001) (Figure 5). These results indicate that the in vitro
PAI-1R effects on matrix degradation are plasmin mediated.
Study 2
In vivo effect of blocking plasmin/plasminogen with TA on
the therapeutic effect of PAI-1R. Urinary protein excretion:
Disease-induced increases in urinary protein excretion were
reduced 57% by PAI-1R treatment (Figure 6). Administration
of TA with PAI-1R did not reverse the therapeutic effect of
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Figure 4 | Plasmin activity in cultured supernatant after 72 h treatment was determined by a (a) chromogenic substrate assay and
(b) 4–16% Zymogram. In the Zymogram assay, equal amount of culture supernatant was separated by 4–16% Zymogram (blue casein) gel.
The gels were then incubated in the NOVEX zymogram renaturing buffer twice for 30 min at room temperature, and then incubated at
371C overnight in NOVEX zymogram developing buffer. The gel was photographed by a Bio-Rad GS-700 imaging densitometer (Bio-Rad
Laboratories, Inc., Hercules, CA, USA). *Po0.05 vs Control, #Po0.05 vs wt-PAI-1 treated.
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Figure 5 | Effects of plasmin inhibitors on the ability of PAI-1R to
normalize the wt-PAI-1-induced inhibition of ECM degradation.
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PAI-1R on protein excretion. TA did not affect the urinary
protein excretion in normal and disease control rats.
Matrix accumulation. periodic acid Schiff (PAS) staining:
Representative glomeruli stained with PAS are shown in
Figure 7. Glomeruli from the disease control rats showed
marked accumulation of ECM at d6 (Figure 7b) compared
with normal glomeruli (Figure 7a). Treatment of nephritic
rats with PAI-1R resulted in a significant reduction in
mesangial ECM accumulation in glomeruli (Figure 7c),
which was reversed by administration of TA (Figure 7f). TA
administration had no effect on matrix accumulation in
either normal or disease control animals (Figures 7d and e).
Quantitative analysis of PAS scoring presented graphically
in Figure 7g indicates that administration of TA com-
pletely blocks the therapeutic effect of PAI-1R on matrix
accumulation.
Immunofluorescent staining: Specific staining of glome-
rular proteins revealed that PAI-1R treatment significantly
reduced the disease-induced increases in fibrinogen/fibrin,
fibronectin (FN) EDAþ , collagen I, and collagen III depo-
sition by 31, 37, 36, and 52%, respectively (Figure 8). These
effects were reversed by administration of TA. No differences
in staining were seen in normal or disease control animals
untreated or treated with TA.
Glomerular transforming growth factor b1 (TGFb1) and
fibronectin production: Glomeruli isolated from d6 diseased
animals showed a 10.4-fold increase in fibronectin produc-
tion (Figure 9a) and a 4.7-fold increase in TGFb1 production
compared to normal glomeruli (Figure 9b). FN and TGFb1
production were reduced with PAI-1R treatment by 49%
(Po0.001) and 33% (Po0.05), respectively (Figure 9).
Administration of TA with PAI-1R had no effect on either
FN or TGFb1 production.
TGFb1, PAI-1, fibronectin, and type I collagen mRNA levels:
As shown in Figure 10, PAI-1R administration had no effect
on the disease-induced overexpression of TGFb1 and PAI-1
mRNAs. In contrast, PAI-1R treatment significantly reduced
the levels of FN-EDAþ and type 1 collagen mRNAs by 26%
(Po0.001) and 44% (Po0.001), respectively. TA adminis-
tration had no effect on expression of these mRNAs in any
group.
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Figure 6 | Effect of TA on 24-h urinary protein excretion from d5
to d6. *Po0.05 vs normal control (NC). #Po0.05 vs disease control
(DC).
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Figure 7 | Glomerular histology. Representative photomicrographs
of glomeruli from normal control rats treated (d) with or (a) without
TA, disease control rats treated (e) with or (b) without TA, and PAI-1R
treated nephritic rats treated (f) with or (c) without TA at d6.
(g) Graphic representation of PAS staining scores of each group.
A total of 30 glomeruli per animal were scored for PAS staining,
scores were averaged for each animal, and then for each group.
*Po0.05 vs normal control (NC). #Po0.05 vs disease control (DC).
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Figure 8 | Immunofluorescent staining score for ECM proteins at
d6. FITC-conjugated rabbit anti-human fibrinogen/fibrin (DAKO,
Carpinteria, CA, USA) was used directly. Monoclonal mouse anti-
cellular fibronectin EDAþ (Harlan Sera-Lab Belton, England), goat
anti-human type I collagen and goat anti-human type III collagen
(Southern Biotechnology Associates, Birmingham, AL, USA) were
used as primary antibodies with FITC-conjugated rat F (ab0)2
anti-mouse immunoglobulin G (Hþ l) (Jackson Immunoresearch
laboratories, West Grove, PA, USA) and FITC-conjugated rabbit
anti-goat immunoglobulin G (DAKO) as secondary antibodies. A total
of 20 glomeruli per animal were scored for immunofluorescent
staining, scores were averaged for each animal, and then for
each group. *Po0.05 vs normal control (NC). #Po0.05 vs disease
control (DC).
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Monocyte/macrophage infiltration: The number of mono-
cyte/macrophage cells increased from 2.370.32 in normal
animals to 12.870.4 in disease control animals (Po0.001,
Figure 11). PAI-1R administration reduced this number by
48%, to 7.770.9 (Po0.001). Co-administration of PAI-1R
and TA partially, but not completely, reversed the elevated
number of monocyte/macrophage cells. TA alone had no
effect on cell number in either normal or disease control
animals.
DISCUSSION
In order to study ECM degradation under well-defined
conditions, we developed an in vitro system utilizing MCs
cultured on extracellular matrices produced by MCs them-
selves, which contain similar matrix components to those
seen in vivo. Utilizing this system, we confirmed that ECM
degradation by cultured rat MCs is dependent upon added
plasminogen and is mediated by plasmin. The fact that
addition of uPA or tPA was not required for matrix degra-
dation confirm other in vitro studies showing that MCs
produce uPA and tPA. These data indicate that ECM
degradation by cultured rat MCs is dependent on the
presence of a functioning PA/plasminogen/plasmin system.
As the primary in vivo inhibitor of both PAs, PAI-1 tightly
regulates this system and increased PAI-1 levels can drama-
tically reduce plasmin generation. Addition of PAI-1R, a
mutant that binds to Vn but does not inhibit PAs, did not
affect plasmin activity or matrix degradation in this system.
This is probably because rat MCs in culture produce only
about 1 109 M PAI-1 after 72 h of incubation (unpublished
observation) so there would be very little endogenous PAI-1
with which PAI-1R might compete. Therefore, exogenous wt-
PAI-1 was added to simulate the disease condition where
glomeruli produce approximately 25-fold greater PAI-1 than
normal glomeruli.23 Addition of 1.5 107 M exogenous wt-
PAI-1 dramatically inhibited plasmin activity and ECM
degradation, an effect lasting at least 72 h. It is likely that Vn
binding stabilizes the wt-PAI-1 in the active conformation
maintaining inhibition for at least 72 h.
When PAI-1R and wt-PAI-1 were added together, the
inhibition of ECM degradation seen with wt-PAI-1 was
reversed in a time- and dose-dependent manner. In addition,
the plasmin activity and casein-degrading capacity of culture
supernatant were partially restored. These data suggest that
PAI-1R successfully competes with wt-PAI-1 for Vn binding
sites. When wt-PAI-1 binds a protease, it loses its affinity for
Vn and is internalized and degraded. PAI-1R, by virtue of its
inability to undergo the reactive center loop conformational
change remains bound to Vn longer than wt-PAI-1. In this
way, PAI-1R restores plasmin generation, which increases
plasmin-dependent degradation of ECM components. That
three inhibitors of plasmin, a2-antiplasmin, aprotinin, and
TA, completely blocked PAI-1R’s ability to normalize ECM
degradation further confirms the plasmin dependence of
ECM degradation in cultured MCs. Interestingly, while
PAI-1R reverses the wt-PAI-1 effect on degradation almost
completely, PAI-1R in the presence of wt-PAI-1 restores
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Figure 10 | Effect of TA on glomerular mRNA expression of
TGF-b1, PAI-1, fibronectin, and collagen I harvested 6 days after
induction of glomerulonephritis. Representative Northern blot is
shown in (a) and relative glomerular mRNA expression was shown in
(b). *Po0.05 vs normal control (NC). #Po0.05 vs disease control (DC).
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Figure 11 | Number of monocytes/macrophages infiltrating
glomeruli in anti-thy-1 nephritis at d6. *Po0.05 vs normal
control (NC). #Po0.05 vs disease control (DC).
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plasmin activity to only 38% of that seen with PAI-1R alone
(Figure 4). This result suggests that in this system a 38%
restoration of plasmin activity by PAI-1R is sufficient to
almost completely reverse the inhibition of matrix degrada-
tion by wt-PAI-1.
Next, we asked whether enhanced plasmin-dependent
matrix degradation is involved in the therapeutic effects of
PAI-1R in anti-thy-1 nephritis. The plasmin inhibitor TA was
used to see if the therapeutic effect of PAI-1R was reversed
when both PAI-1R and TA were given, a finding that would
indicate plasmin dependence of the therapeutic effect.
Administration of TA to PAI-1R-treated nephritic rats
resulted in an interesting picture in that the therapeutic
actions of PAI-1R fall into three categories with respect to
plasmin-dependence. First, the PAI-1R-induced effect on
pathological matrix accumulation, as indicated by PAS score,
FN, Collagen I, and Collagen III staining, was completely
reversed by TA treatment indicating plasmin dependence of
these therapeutic actions. In contrast, TA had no effect on
other measures of disease including urinary protein, FN, and
TGFb1 production by nephritic glomeruli in culture or FN
and Collagen I mRNA levels. Therefore, these are plasmin-
independent therapeutic effects of PAI-1R. A third category
of effect was seen with the number of ED-1þ cells per
glomerulus. Co-administration of PAI-1R and TA partially,
but not completely, reversed the infiltration of monocyte/
macrophage cells suggesting a combination of plasmin-
independent and plasmin-dependent mechanisms.
These data are very interesting when compared with those
we obtained by treating nephritic rats with tPA.24 t-PA
enhances plasmin generation and subsequent matrix degra-
dation without altering any disease markers except those of
matrix accumulation suggesting a pure plasmin-dependent
effect of tPA. The current data indicate that PAI-1R treatment
also enhances plasmin generation but, because other
measures of disease were altered, suggests that PAI-1R has
other actions in addition to enhancing plasmin generation.
No effect of TA was detected in normal animals suggesting
that blocking the normal actions of plasminogen/plasmin did
not affect the variables measured here in the 5 days of
treatment. TA also had no measurable effect in disease
control animals. This is probably because the dramatically
increased PAI-1 in disease control kidney already maximally
blocks plasmin generation from plasminogen.
Combined with the in vitro data that PAI-1R enhances
plasmin-mediated degradation of matrix proteins, these
in vivo data support the hypothesis that part of the thera-
peutic effect of PAI-1R in renal fibrosis is to enhance
plasmin-dependent ECM degradation. These data further
support the notion that PAI-1R has multiple actions on
important measures of disease severity. However, because it is
the accumulation of matrix that ultimately obliterates organ
function, we conclude that PAI-1R actions to enhance matrix
degradation are key to its antifibrotic effect, at least in this
model of disease. It will be interesting to see if plasmin-
independent actions of PAI-1R on disease severity, particu-
larly macrophage/monocyte infiltration, produce an effect on
ECM accumulation in longer-term models of renal fibrosis.
In summary, these in vitro and in vivo observations
provide convincing evidence that PAI-1R reduces pathologi-
cal ECM accumulation in anti-thy-1 nephritis through
effectively competing with native PAI-1 for Vn binding sites,
thereby restoring plasmin generation and increasing plasmin-
dependent degradation of matrix components.
MATERIALS AND METHODS
Study 1. In vitro studies of the effects of mutant PAI-1R on
ECM degradation by MCs
Materials. Unless otherwise indicated, materials, chemicals,
and culture media were purchased from Sigma-Aldrich (St Louis,
MO, USA). Wild-type PAI-1 (wt-PAI-1) was produced as an active
form in Escherichia coli.25
Production of radioactive matrices. Rat MC matrices were
obtained as described previously.26,27 Briefly, MCs were seeded into
six-well plates at 2 105 cells/well. Ascorbic acid (25 mg/ml) was
added to the culture on the second day and daily thereafter. The
medium was changed twice weekly. L-(2,3-3H)-proline was added to
the culture medium at 0.5 mCi/ml on days 3, 7, and 10 after seeding.
At 2 weeks after seeding of the cells, cultures were washed with
phosphate-buffer saline and the cells were lysed by treatment with
2 ml 2.5 mM NH4OH, 0.1% Triton X-100 for 2 min. The matrices
were then washed extensively with distilled water and kept covered
with distilled water under sterile conditions at 41C until further use.
Characterization of matrix produced by MCs in culture. ECM
was produced by MCs without added L-(2,3-3H)-proline. Rabbit
anti-human type IV collagen antibody (Rockland), monoclonal
mouse anticellular fibronectin extra domain positive (EDAþ )
(Harlan Sera-Lab Belton, England), rabbit anti-mouse laminin
(Cappel, Aurola, OH, USA), and rabbit anti-mouse Vn antibody
(kindly provided by Emile de Heer, Department of Nephrology and
Pathology, Leiden University Medical Center, Leiden, The Nether-
lands) were used as the primary antibodies for detection of matrix
components produced by MCs in vitro. Fluorescence in situ
hybridization-conjugated swine anti-rabbit immunoglobulin G
(DAKO, Corp.) and fluorescein isothiocyanate (FITC)-conjugated
rat F(ab0)2 anti-mouse immunoglobulin G (Hþ l) (Jackson
ImmunoResearch Laboratories Inc.) were used as the secondary
antibodies. Adding either phosphate-buffer saline or nonimmunized
normal serum instead of primary antibodies serve as control.
Degradation of matrices by MCs. Labeled matrices were
washed three times with 2 ml of serum-free RPMI-1640 medium
before addition of MCs in 15% fetal calf serum RPMI-1640
medium. Plates were incubated for 24 h to allow the MCs to attach
and to recover from plating. After 24 h, the medium was removed,
cells were washed three times with 2 ml of serum-free RPMI-1640
medium to remove proteolytic enzyme inhibitors potentially present
in the serum and incubated for 72 h in 2 ml of serum-free RPMI-
1640 containing 0.2% lactalbumin hydrolyzate (RPMI-LH).26
Exogenously added agents were dissolved in RPMI-LH at the
concentrations indicated below. At the end of the incubation, the
radioactivity in culture supernatant, representing digested matrix,
was measured in a scintillation counter. The matrix remaining on
the plate was digested with 2 N NaOH and its radioactivity
measured. Background values obtained with medium (RPMI-LH)
in the absence of cells were subtracted from these values. The sum of
counts in the supernatant and residual undigested matrix was
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considered 100%. Percent matrix degradation was calculated as
supernatant counts divided by total counts 100. A plasmin-
specific chromogenic substrate, Chromozym PL (Roche Molecular
Biochemicals, Indianapolis, IN, USA) was used to measure plasmin
activity as described.18 A measure of 80 ml of cultured supernatant
and 20ml 3 mM Chromozyme PL (Diapharma Group Inc. West
Chester, OH, USA) were added per well. The rate of increase in
absorbance, corresponding to plasmin activity, was measured over a
2 h interval. A standard curve was generated with serial dilutions of
porcine plasmin. Results were expressed as 104 U/ml.
Zymography. To further determine plasmin activity in cul-
tured supernatant, 30 ml of each supernatant was separated by a
4–16% Tris-Glycine gel with blue-stained b-casein incorporated as a
substrate for plasmin (NOVEX, San Diego, CA, USA). Plasmin
activity was seen as clear bands against a dark blue background
where plasmin had digested casein.
Study 2. Plasmin dependence of the therapeutic effect of
PAI-1R in experimental glomerulonephritis
Animals. Male Sprague–Dawley rats (180–200 g) obtained from
the SASCO colony of Charles River Laboratories (Wilmington, MA,
USA) were used. Animal housing and care were in accordance with
the NIH Guide for the Care and Use of Laboratory Animals, NIH
Publication No. 85–23, 1985. Glomerulonephritis was induced by
tail vein injection of the monoclonal anti-thy-1 antibody OX-7
(NCCC; Biovest International, Inc., Minneapolis, MN, USA) as
previously described.28 Normal control animals were injected with
the same volume of phosphate-buffer saline.
Experimental design. Initial experiments revealed that a dose
of TA equivalent to that used in mice22 produced diarrhea and
wasting in rats. Thus, a pilot experiment was carried out to
determine an effective and safe dose of TA in normal rats. TA
(18 mg/day) was administered to four groups of three rats by
continuous subcutaneous infusion via osmotic pumps (model
2 ml1; ALZA Corp., Palo Alto, CA, USA) implanted under the
dorsal skin of rats. In addition, three doses of TA from 0.02 to 20 g/l
were given in drinking water to supplement the parenteral dose. All
rats were killed at day 4. The results indicated that 18 mg/day in
osmotic pumps plus 2 g/l in drinking water produced no diarrhea or
wasting, and this dose was used in further experiments. Eight rats/
group were assigned to groups including normal controls, normal
rats treated with TA, disease controls, diseased rats treated with TA,
diseased rats treated with PAI-1R, and diseased rats treated with
PAI-1R and TA. PAI-1R was administered intraperitoneally twice a
day from day 1 to d5 at a dose of 1 mg/kg body weight. TA was given
from d1 to d5. At 24-h urinary protein excretion was measured by
the Bradford method (Bio-Rad Protein Assay; Bio-Rad Laboratories
Inc., Hercules, CA, USA) on urine collected from rats housed in
metabolic cages from d5 to d6.
On day 6, animals were anesthetized, 5–10 ml blood was drawn
from the lower abdominal aorta and kidneys were perfused with
30 ml ice-cold phosphate-buffer saline. For histological examination,
cortical tissue was snap frozen for frozen sectioning or fixed in 10%
neutral-buffered formalin for PAS staining. Glomeruli were isolated
by graded sieving as described previously.29 Analysis of glomerular
production of FN and TGF-b1 were carried out by enzyme-linked
immunosorbent assay as described.18
Histological analyses. All microscopic examinations were
performed in a blinded fashion. Three micrometer sections of
paraffin-embedded tissues were stained with PAS. Glomerular
matrix expansion was evaluated in 30 glomeruli from each rat
where the percentage of mesangial matrix occupying each
glomerulus was rated on a 0–4 scale where 0¼ 0, 1¼ 25, 2¼ 50,
3¼ 75, or 4¼ 100% as previously described.30 Immunofluorescent
staining for matrix proteins was performed on frozen sections as
described.18 Monocyte/macrophage infiltration into glomeruli was
assessed using FITC-conjugated mouse anti-rat ED-1 antibody
(Serotec, Oxford, UK). Intraglomerular deposition of fibrinogen/
fibrin, Fn-EDAþ , collagen I and collagen III was quantified by
scoring 20 randomly selected glomeruli on a 0–4 scale as described
above. The number of monocyte/macrophage cells per glomerulus
was counted in 20 glomeruli selected randomly per section.
RNA preparation and northern hybridization. Total RNA was
extracted immediately from isolated glomeruli using TrizolTM
Reagent (GibcoBRL, Gaithersburg, MD, USA), according to the
manufacturer’s instructions. RNA from each group was pooled and
Northern analysis was performed as previously described.18 Three
blots per probe were performed. Autoradiographic films were
scanned on a Bio-Rad GS-700 imaging densitometer (Bio-Rad
Laboratories, Inc., Hercules, CA, USA). For quantitative densito-
metric measurements of Northern blots, all the signals were
normalized in comparison with glyceraldehyde-3-phosphate dehy-
drogenase levels used for equal loading.
Statistics and calculation of percentage reduction in disease
severity. Data are expressed as mean7s.e.m. Statistical signifi-
cance between groups was analyzed by Student’s t-test or Welch’s t-
test. Po0.05 was considered statistically significant. The disease-
induced increase in a variable was defined as the mean value for the
disease control group minus the mean value of the normal control
group (100%). The percent reduction in disease severity in a PAI-
1R-treated group was calculated as follows:
f1-ðPAI-1R-treated group mean  normal control
group meanÞ=ðdisease control group mean
normal control group meanÞg100:
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